ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 1955

Ultrasound for Screening of Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review and Meta Analysis

Ikwinder Preet Kaur1, Karishma Ramsubeik2, Thway Myant3, Luis Sanchez-Ramos4, Laurie Ramrattan5 and Gurjit Kaeley6, 1University of Florida College of Medicine, Jacksonville, FL, 2Baptist Health, Jax, FL, 3UF Jacksonville, Mia, FL, 4University of Florida college of Medicine, Jacksonville, 5University of Florida, Jacksonville, FL, 6UF COM-J, Ponte Vedra Beach, FL

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: interstitial lung disease, rheumatoid arthritis, Ultrasound

Session Information

Date: Monday, November 18, 2024

Title: Imaging of Rheumatic Diseases Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Clinically significant Interstitial Lung Disease (ILD) can occur in up to 10 percent of  Rheumatoid Arthritis (RA) patients, which is associated with considerable morbidity and mortality.  It presents a 2-10-fold higher hazard ratio for mortality compared to RA without ILD, making its early detection imperative. The 2024 guidelines recommend HRCT and pulmonary function tests (PFTs) for initial screening and monitoring of ILD. However, HRCT exposes patients to radiation, and PFTs may lack sensitivity in early disease stages. Lung Ultrasound (LUS) offers a promising alternative due to its portability and lack of radiation. Sonographic characteristics such as identifying and quantifying B lines and identifying pleural irregularities might be signs of ILD.  This study investigates the diagnostic accuracy of LUS for RA-ILD compared to HRCT.

Methods: This PRISMA-compliant systematic review and meta-analysis searched EMBASE, PubMed, Web of Science, and Scopus  for English literature studies from year 2000-2023. Studies with at least 20 RA patients evaluating LUS for RA-ILD compared to HRCT were included. Review articles, conference abstracts, case series with less than 20 patients, treatment outcome studies without controls, and non-RA ILD or healthy control studies were excluded. Summary diagnostic accuracy, including sensitivity, specificity, and area under the curve (AUC) was analyzed utilizing Stata software. A diagnostic test meta-analysis using a bivariate model was performed to calculate the pooled sensitivity, specificity, positive/negative likelihood ratios and DOR. We also constructed the respective hierarchical summary receiver-operating characteristic (HSROC) curve to summarize the paired sensitivity and specificity estimates instead of the traditional SROC model.

Results: Four studies encompassing 324 RA patients (140 with HRCT-confirmed ILD) were included. The mean age was slightly higher in the RA-ILD group (61.3 years) compared to the RA-no ILD group (59 years). Notably, 68% of patients in the RA ILD group for smokers as compared to 31 percent in the RA-no ILD  group.  Analysis revealed significant heterogeneity across studies regarding ultrasound machines (probe frequency ranged from 1-13 mHZ), lung segments examined (14 to 72), and B-line cut-off ( >/=5 to 10) values. The pooled sensitivity for LUS was  95% (95% CI  41- 100%; I2 =86%) and specificity was 98% (95% CI  64-100%; I2 =86%) representing an overall high sensitivity and specificity;  however with a significant heterogeneity.  The Area under the curve (AUC)  was 99% (95% CI 98-100%)  suggesting relatively high accuracy (Images 1 and 2). The two of the studies demonstrated a positive correlation of LUS B-lines with HRCT ( 0.806 and 0.944),  and the other two did not comment on this. 

Conclusion: This meta-analysis highlights that LUS  may hold remarkable potential for RA-ILD screening  due to it’s real-time visualization, and high diagnostic accuracy. However, significant heterogeneity across studies regarding LUS protocols necessitates standardization to improve generalizability. Further research with more comprehensive studies with larger sample sizes and more rigorous methodologies is necessary to validate study findings. 

Supporting image 1

Image 1- Paired forest plots’ sensitivity and specificity for LUS compared to HRCT to detect ILD in rheumatoid arthritis patients

Supporting image 2

Image 2- HSROC curve to summarize the paired sensitivity and specificity estimates. (The HSROC is the graphical depiction of a random-effects model that includes estimates of the between-study variance. The closeness of the main solid curve to the top left indicates a high overall accuracy. The prediction region (enclosed by the small dashed line) was larger than the confidence region (enclosed by the larger dashed line), which also suggests high heterogeneity)


Disclosures: I. Kaur: None; K. Ramsubeik: None; T. Myant: None; L. Sanchez-Ramos: None; L. Ramrattan: None; G. Kaeley: AbbVie/Abbott, 5, Bristol-Myers Squibb(BMS), 5, Gilead, 5, Janssen, 5, Novartis, 5.

To cite this abstract in AMA style:

Kaur I, Ramsubeik K, Myant T, Sanchez-Ramos L, Ramrattan L, Kaeley G. Ultrasound for Screening of Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review and Meta Analysis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/ultrasound-for-screening-of-rheumatoid-arthritis-associated-interstitial-lung-disease-a-systematic-review-and-meta-analysis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ultrasound-for-screening-of-rheumatoid-arthritis-associated-interstitial-lung-disease-a-systematic-review-and-meta-analysis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology